Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160042/S029

Revanesse Versa; Revanesse Versa+ (with lidocaine); Revanesse Lips+ (with lidocaine)

Prollenium Medical Technologies, Inc. · Decision date Dec 22, 2025

FDA DECISIONP160042/S029

What did the FDA decide?

FDA records P160042/S029 as a supplement to PMA P160042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 22, 2025.

FDA approval order statement

approval for modifications to cleanroom layout in a secondary manufacturing facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Dec 22, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160042/S029
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
OK30
Decision date
Dec 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P160042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160042/S029 received

    Application receipt date recorded by FDA.

  2. P160042/S029 · FDA decision

    30-Day Notice

  3. P160042/S031 · Related supplement

    Revanesse Versa / Revanesse Versa+ (with lidocaine) / Revanesse Lips+ (with lidocaine)

  4. P160042/S032 · Related supplement

    Revanesse Versa, Revanesse Versa+ (with lidocaine) and Revanesse Lips+ (with lidocaine)

Timeline entries are records held by MedtechLedger for P160042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160042

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Prollenium Medical Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
138 Industrial Pkwy. N., Aurora, L4G 4C3

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records